Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation.
Rogava M, Aprati TJ, Chi WY, Melms JC, Hug C, Davis SH, Earlie EM, Chung C, Deshmukh SK, Wu S, Sledge G, Tang S, Ho P, Amin AD, Caprio L, Gurjao C, Tagore S, Ngo B, Lee MJ, Zanetti G, Wang Y, Chen S, Ge W, Melo LMN, Allies G, Rösler J, Gibney GT, Schmitz OJ, Sykes M, Creusot RJ, Tüting T, Schadendorf D, Röcken M, Eigentler TK, Molotkov A, Mintz A, Bakhoum SF, Beyaz S, Cantley LC, Sorger PK, Meckelmann SW, Tasdogan A, Liu D, Laughney AM, Izar B. Rogava M, et al. Among authors: sledge g. Nat Cancer. 2024 Mar;5(3):433-447. doi: 10.1038/s43018-023-00704-x. Epub 2024 Jan 29. Nat Cancer. 2024. PMID: 38286827 Free PMC article.
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.
Muquith M, Espinoza M, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H, Hsiehchen D. Muquith M, et al. Nat Cancer. 2024 Jul;5(7):1121-1129. doi: 10.1038/s43018-024-00752-x. Epub 2024 Mar 25. Nat Cancer. 2024. PMID: 38528112
Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors.
Chowdhury S, Xiu J, Ribeiro JR, Nicolaides T, Zhang J, Korn WM, Poorman KA, Lenz HJ, Marshall JL, Oberley MJ, Sledge GW Jr, Spetzler D, Kopetz S, Shen JP. Chowdhury S, et al. Among authors: sledge gw jr. Br J Cancer. 2024 Nov;131(8):1328-1339. doi: 10.1038/s41416-024-02826-0. Epub 2024 Sep 4. Br J Cancer. 2024. PMID: 39227409
Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung Cancer.
Watson AS, Krause HB, Elliott A, Farrell A, Liu SV, Ma PC, VanderWalde A, Sledge GW, Spetzler D, Schenk EL, Camidge DR. Watson AS, et al. Among authors: sledge gw. Clin Lung Cancer. 2024 Dec;25(8):712-722.e1. doi: 10.1016/j.cllc.2024.09.001. Epub 2024 Sep 12. Clin Lung Cancer. 2024. PMID: 39384504
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation.
Hsiehchen D, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H. Hsiehchen D, et al. Among authors: sledge gw. Cancer Cell. 2024 Dec 9;42(12):1985-1987. doi: 10.1016/j.ccell.2024.10.017. Epub 2024 Nov 21. Cancer Cell. 2024. PMID: 39577419
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes.
Zorko NA, Makovec A, Elliott A, Kellen S, Lozada JR, Arafa AT, Felices M, Shackelford M, Barata P, Zakharia Y, Narayan V, Stein MN, Zarrabi KK, Patniak A, Bilen MA, Radovich M, Sledge G, El-Deiry WS, Heath EI, Hoon DSB, Nabhan C, Miller JS, Hwang JH, Antonarakis ES. Zorko NA, et al. Among authors: sledge g. Prostate Cancer Prostatic Dis. 2024 Feb 28:10.1038/s41391-024-00797-0. doi: 10.1038/s41391-024-00797-0. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38418892
The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors.
Kareff SA, Trabolsi A, Krause HB, Samec T, Elliott A, Rodriguez E, Olazagasti C, Watson DC, Bustos MA, Hoon DSB, Graff SL, Antonarakis ES, Goel S, Sledge G, Lopes G. Kareff SA, et al. Among authors: sledge g. Cancers (Basel). 2024 Apr 19;16(8):1572. doi: 10.3390/cancers16081572. Cancers (Basel). 2024. PMID: 38672653 Free PMC article.
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).
Mezzanotte-Sharpe J, ONeill A, Mayer IA, Arteaga CL, Yang XJ, Wagner LI, Cella D, Meropol NJ, Alpaugh RK, Saphner TJ, Swaney RE, Hoelzer KL, Gradishar WJ, Abramson VG, Sundaram PK, Jilani SZ, Perez EA, Lin NU, Jahanzeb M, Wolff AC, Sledge GW, Reid SA. Mezzanotte-Sharpe J, et al. Among authors: sledge gw. Breast Cancer Res Treat. 2024 Sep;207(2):275-282. doi: 10.1007/s10549-024-07417-4. Epub 2024 Jul 5. Breast Cancer Res Treat. 2024. PMID: 38967884 Free PMC article. Clinical Trial.
Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy.
Bansal R, Adeyelu T, Elliott A, Tan AR, Ribeiro JR, Meisel J, Oberley MJ, Graff SL, Sledge GW Jr, Grilley-Olson JE, Sammons SL, Rosenberger LH. Bansal R, et al. Among authors: sledge gw jr. JCO Precis Oncol. 2024 Dec;8:e2400289. doi: 10.1200/PO.24.00289. Epub 2024 Dec 5. JCO Precis Oncol. 2024. PMID: 39637336 Free PMC article.
454 results